France Funded Two Cancer Drugs the Same Week. One Was Rated Therapeutic Progress, One Was Not.
Listing is granted by indication, not by licence. Columvi is funded for one situation and refused for the rest of its authorisation.
Roche
Roche Paid $190 Million Up Front on a $2.3 Billion Headline for a Phase 1 Obesity Asset
https://synopulse.com/wp-content/uploads/2026/08/Roche-Paid-190-Million-Up-Front-on-a-2.3-Billion-Headline-for-a-Phase-1-Obesity-Asset.webp
Canada Moved Two Cancer Drugs Forward in One Week. Neither Went the Normal Route.
One drug reached review only because payers filed for a manufacturer that had not. The other was recommended on evidence the committee called inconclusive.
Wet AMD’s Problem Was Never the Drug. It Was the Injections.
Susvimo won a CHMP recommendation as Europe’s first continuous-delivery wet AMD treatment, replacing monthly eye injections with two implant refills a year.
Groundbreaking Collaboration Between Manifold Bio and Roche Launches $2B-Plus Brain-Shuttle Program
Manifold Bio inks a groundbreaking collaboration with Roche to apply AI-guided brain-shuttle technology for neurological therapies.
Stratipath And Roche Collaborate To Expand Access To Ai-powered Breast Cancer Diagnostics
Stratipath, a leader in AI-based precision diagnostic solutions, has announced a collaboration with Roche, the world’s largest biotechnology company and a global leader in in-vitro diagnostics. Through this partnership, Roche gains distribution rights to Stratipath’s AI-driven diagnostic tool, Stratipath Breast. This solution integrates seamlessly with Roche’s navify® Digital Pathology enterprise software, allowing users to perform … Read more